INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 20, 2007 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $8.77 | 29,297 |
| Apr 20, 2007 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | 25,000 |
| Jun 19, 2012 |
SVP Res & Dev Sciences
|
SVP Res & Dev Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 24,848 | $115.60 | 73,184 |
| Jul 27, 2009 |
SVP Res and Dev Sciences
|
SVP Res and Dev Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 24,686 | $20.74 | 2,550 |
| Dec 11, 2019 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 24,500 | -- | 24,500 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,226 | $10.56 | 33,873 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Open market or private sale of non-derivative or derivative security | 24,226 | $20.00 | 9,647 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,226 | -- | 7,463 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,000 | $7.41 | 27,127 |
| Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.